AstraZeneca's global biologics research and development arm, MedImmune, has completed its acquisition of Amplimmune, in a deal worth up to US $500 million. Amplimmune is a US-based biologics ...
When AstraZeneca acquired MedImmune in 2007 for $15 billion, some analysts felt the firm overpaid for the biotech company. This week, MedImmune celebrates its 25th anniversary – and has come to ...
"For more than two decades Aaron has earned the trust of life science leaders for his deep expertise in the industry and delivering for his clients," said Curtis Lane, Founding Partner of MTS. "We are ...
Results that may be inaccessible to you are currently showing.